Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

被引：0
|
作者：
Moskowitz, Craig H.
Chen, Robert W.
Armand, Philippe
Zinzani, Pier Luigi
Vassilakopoulos, Theodoros P.
Goldmacher, Gregory V.
Lin, Jianxin
Nahar, Akash
Balakumaran, Arun
Salles, Gilles
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4085
引用
收藏
页数：4
相关论文
共 36 条
  • [31] Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy
    Kuruvilla, John
    Ramchandren, Radhakrishnan
    Santoro, Armando
    Paszkiewicz-Kozik, Ewa
    Gasiorowski, Robin
    Johnson, Nathalie A.
    Fogliatto, Laura Maria
    Goncalves, Iara
    de Oliveira, Jose
    Buccheri, Valeria
    Perini, Guilherme Fleury
    Goldschmidt, Neta
    Kryachok, Irina
    Sekiguchi, Naohiro
    Lin, Jianxin
    Nahar, Akash
    Marinello, Patricia
    Zinzani, Pier Luigi
    BLOOD, 2020, 136
  • [32] Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study
    Zinzani, Pier Luigi
    Ramchandren, Radhakrishnan
    Santoro, Armando
    Paszkiewicz-Kozik, Ewa
    Gasiorowski, Robin
    Johnson, Nathalie A.
    de Oliveira, Jose S. R.
    Buccheri, Valeria
    Perini, Guilherme Fleury
    Dickinson, Michael
    McDonald, Andrew
    Ozcan, Muhit
    Sekiguchi, Naohiro
    Raut, Monika
    Giezek, Hilde
    Nahar, Akash
    Kuruvilla, John
    BLOOD, 2020, 136
  • [33] Comparison of interim PET (iPET) response to relapse vs. first-line treatment in children with classical Hodgkin lymphoma (HL) - contribution to the development of response criteria for relapsed HL
    Kluge, Regine
    Wittig, Tim
    Hasenclever, Dirk
    Kurch, Lars
    Georgi, Thomas
    Sabri, Osama
    Mauz-Krholz, Christine
    Koerholz, Dieter
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [34] Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
    Kluge, Regine
    Wittig, Tim
    Georgi, Thomas W.
    Kurch, Lars
    Sabri, Osama
    Wallace, W. Hamish
    Klekawka, Tomasz
    Fernandez-Teijeiro, Ana
    Ceppi, Francesco
    Karlen, Jonas
    Pears, Jane
    Cepelova, Michaela
    Fossa, Alexander
    Beishuizen, Auke
    Hjalgrim, Lisa Lyngsie
    Koerholz, Dieter
    Mauz-Koerholz, Christine
    Hasenclever, Dirk
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (03) : 338 - 341
  • [35] Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008
    Lavie, David
    Timmerman, John
    Garcia-Sanz, Ramon
    Kim, Won Seog
    Kim, Tae Min
    Avigdor, Abraham
    Dierickx, Daan
    Jagadeesh, Deepa
    Molin, Daniel L.
    Ozcan, Muhit
    Sevindik, Omur Gokmen
    Saeed, Hayder
    Sidi, Yulia
    Pillai, Pallavi
    Marinello, Patricia
    Herrera, Alex F.
    BLOOD, 2023, 142
  • [36] Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
    Zinzani, P. L.
    Ramchandren, R.
    Santoro, A.
    Paszkiewicz-Kozik, E.
    Gasiorowski, R.
    Johnson, N. A.
    de Oliveira, J. S. R.
    Buccheri, V.
    Perini, G. F.
    Dickinson, M.
    McDonald, A.
    Ozcan, M.
    Sekiguchi, N.
    Raut, M.
    Zhu, Y.
    Nahar, A.
    Marinello, P.
    Kuruvilla, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S649 - S649
1234